Putnam Investments’s ANI Pharmaceuticals ANIP Stock Holding History

Putnam Investments’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-78,699	Closed	-$3.68M	–	1112
2017 Q2	$3.68M	Buy	78,699 +57,024	+263%	+$2.75M	0.01%	598
2017 Q1	$1.07M	Sell	21,675 -2,551	-11%	-$143K	﹤0.01%	986
2016 Q4	$1.47M	Sell	24,226 -249	-1%	-$15.2K	﹤0.01%	912
2016 Q3	$1.62M	Sell	24,475 -15,720	-39%	-$983K	﹤0.01%	904
2016 Q2	$2.24M	Buy	+40,195	New	+$1.95M	0.01%	893

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Putnam Investments's ANIP Position: Q3 2017 in Review

Putnam Investments sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 78,699 shares — an estimated $3.68M sold.

Putnam Investments first reported a position in ANIP in Q2 2016 and held it in 5 quarters. The position peaked at $3.68M in Q2 2017. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

Putnam Investments reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Putnam Investments sold 78,699 ANI Pharmaceuticals shares in Q3 2017, an estimated $3.68M.
Putnam Investments first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 5 quarters.
Putnam Investments's ANI Pharmaceuticals position peaked at $3.68M in Q2 2017.
146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Putnam Investments's 13F filing for Q3 2017, filed 14 Nov 2017.